Mitsuhiro Yuasa1, Masato Shiiba2, Michiho Ebihara1, Kosei Kageyama1, Daisuke Kaji1, Aya Nishida1, Shinsuke Takagi1, Hisashi Yamamoto1, Yuki Asano-Mori1, Akiko Yoneyama3, Shigeyoshi Makino4, Naoyuki Uchida1, Maikiko Ishihara2, Shuichi Taniguchi1, Go Yamamoto1 (1.Department of Hematology, Toranomon Hospital, Tokyo, Japan, 2.Dignostic Imaging Center, Toranomon Hospital, Tokyo, Japan, 3.Department of Infectious Disease, Toranomon Hospital, Tokyo, Japan, 4.Department of Transfusion Medicine, Toranomon Hospital, Tokyo, Japan, 5.Department of Hematology, National Cancer Center Hospital, Tokyo, Japan)
Session information
Oral Session
Oral Session 3-8D Indolent lymphoma: Clinical studies
Sun. Oct 14, 2018 3:00 PM - 4:00 PM No.8 (Osaka International Convention Center, 10F 1002)
Chair: Noriko Fukuhara (Tohoku University Hospital Department of Hematology of Rheumatology, Japan)
Akie Hirata1, Kaname Miyashita2, Takafumi Tanaka2, Kiyoko Hirata2, Hayato Utsunomiya3, Hirofumi Ohno3, Eriko Nakashima2, Yoshimichi Tachikawa2, Ilseung Choi2, Kenichi Taguchi1, Youko Suehiro2,3 (1.Department of Laboratory Medicine, National Kyushu Cancer Center, 2.Department of Hematology, National Kyushu Cancer Center, 3.Department of Cell Therapy, National Kyushu Cancer Center)
Saeko Kuwahara-Ota, Tsutomu Kobayashi, Yoshimi Mizuno, Tomoko Takimoto-Shimomura, Reiko Isa, Junko Yamaguchi, Daichi Nishiyama, Takahiro Fujino, Taku Tsukamoto, Mio Yamamoto-Sugitani, Yoshiaki Chinen, Yuji Shimura, Shigeo Horiike, Junya Kuroda (Division of Hematology and Oncology,Kyoto Prefecture University of Medicine, Japan)
Kayo Harada-Shirado1, Masahiko Fukatsu1, Takahiro Sano1,3, Satoshi Kimura1, Hiroshi Takahashi1, Akiko Shichishima-Nakamura1, Hiroshi Ohkawara1, Kazuei Ogawa1,2, Hiroyuki Kanbayashi3, Yurie Saitou3, Satoru Kimura3, Masumi Sukegawa7, Kazuko Akutsu5, Youichi Hamazaki5, Tatsuyuki Kai4, Masayuki Mita6, Masatsugu Ohta7, Takayuki Ikezoe1 (1.Department of Hematology, Fukushima Medical University, Fukushima, Japan, 2.Preparing section for new faculty of medical science, FMU, 3.Department of Hematology, Ohta Nishinouchi Hospital, Ohta General Hospital Foundation, 4.Department of Hematology, Kita-Fukushima Medical Center, Fukushima, Japan, 5.Iwaki-kyoritsu General Hospital, Iwaki, Japan, 6.Hematology and Oncology Center, Shirakawa Kosei General Hospital, Shirakawa, Japan, 7.Department of Hematology, Fukushima Medical University Aizu Medical Center)
Kyoko Yoshihara1,7, Yoshifumi Shimizu2,7, Hiroyuki Kawamoto3,7, Hiroyuki Takatsuka4,7, Tazuko Tokugawa1,7, Akihiro Sawada1,7, Satoshi Yoshihara1,5,7, Masaya Okada1,7, Mahito Misawa6,7, Hidetaka Ifuku4,7, Takahiro Okamoto2,7, Yokiko Ooe4,7, Yoshihiro Fujimori1,5,7 (1.Hematology, Hyogo College of Medicine, Hyogo, Japan, 2.Hematology, Takarazuka City Hospital, Hyogo, Japan, 3.Hematology, Uegahara Hospital, Hyogo, Japan, 4.Hematology, Amagasaki Chuo Hospital, Hyogo, Japan, 5.Transfusion Medicine/Cellular Therapy, Hyogo College of Medicine, Japan, 6.Hematology, Ako Central Hospital, Hyogo, Japan, 7.Mukogawa Hematology Study Group, Hyogo, Japan)
Yoshihiro Kameoka1, Atsushi Kitabayashi2, Kumi Ubukawa1, Shinsuke Noguchi3, Hideaki Ohyagi4, Mutsuhito Motegi5, Yoshinari Kawabata2, Hitoshi Ogasawara6, Jun Kuroki7, Takashi Nimura5, Naoto Takahashi1 (1.Hematol., Akita Univ., Akita, Japan, 2.Hematol., Akita Kousei Med. Cen., Akita, Japan, 3.Hematol., Akita Red Cross Hosp., Akita, Japan, 4.Hematol., Hiraka Gen. Hosp., Yokote, Japan, 5.Int., Med., Omagari Kousei Med. Cen., Omagari, Japan, 6.Int., Med., Odate Municipal Gen. Hosp., Odate, Japan, 7.Int., Med., Yuri Kumiai Gen. Hosp., Yurihonjo, Japan)